Navigation Links
AlphaVax Announces New CMV Advisory Board

RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves its CMV vaccine candidates through clinical development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President for Research, the Board members include:

-- Mark Schleiss, MD, Professor, Associate Head for Research and the

American Legion Chair in the Department of Pediatrics and Director,

Division of Infectious Diseases, at the University of Minnesota.

-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,

Infectious Diseases and Director of the Gamble Program at the

Cincinnati Children's Hospital and Medical Center.

-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the

University of Alabama - Birmingham.

-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for

Virology, Division of Infection at Royal Free and University College

Medical School in London.

AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. In addition to programs in influenza and cytomegalovirus, important disease targets include cancer, HIV and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs.

SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
2. ADVENTRX Announces Consolidation of Clinical and Management Positions
3. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
5. BD Announces Results of Shareholder Votes at Annual Meeting
6. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
7. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):